ADPT — Adaptive Biotechnologies Corp
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1478320 ·
Last close
$14.13
Market Cap
$2.26B
52W High
$16.95
52W Low
$12.00
ADV30
1,525,878
Next earnings
2026-08-04
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 70,874,000 | 52,166,000 | -19,206,000 | -20,033,000 | 505,943,000 | 77,581,000 | 281,702,000 |
| Dec 2025 | 71,681,000 | 53,457,000 | -12,773,000 | -13,579,000 | 512,736,000 | 70,495,000 | 287,735,000 |
| Sep 2025 | 93,973,000 | 75,816,000 | 10,290,000 | 9,546,000 | 490,610,000 | 55,034,000 | 286,357,000 |
| Jun 2025 | 58,879,000 | 40,880,000 | -25,036,000 | -25,614,000 | 496,637,000 | 43,163,000 | 317,101,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-45,986,000
Investing CF
$37,950,000
Financing CF
$30,403,000
CapEx
$-2,959,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.40
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,363,323,000
Inventory
$9,820,000
Receivables
$50,365,000
ST Investments
$156,485,000
EBIT TTM
$-47,679,000
Pretax Income TTM
$-59,457,000
Interest Exp TTM
$11,778,000
Analysts
7
Yahoo Snapshot (yfinance, live)
Total Revenue
$295,407,008
EBITDA
$-29,786,000
Free Cash Flow
$16,102,625
Enterprise Value
$2,219,164,160
Total Cash
$218,334,000
Total Debt
$208,180,992
Shares Out
160,044,392
Trailing EPS
$-0.32
Book Value
$1.35
ROE
-24.0%
ROA
-5.7%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 276,976,000 | -57,123,000 | -59,499,000 | 512,736,000 | 287,735,000 | — | -45,986,000 |
| Dec 2024 | 178,957,000 | -155,344,000 | -159,492,000 | 539,376,000 | 336,891,000 | — | -95,212,000 |
| Dec 2023 | 170,276,000 | -201,606,000 | -225,250,000 | 661,134,000 | 352,856,000 | — | -156,324,000 |
| Dec 2022 | 185,308,000 | -200,186,000 | -200,191,000 | 856,617,000 | 392,519,000 | — | -183,945,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.26
Max Pain — expiry 2026-06-18 (volume-derived — Yahoo OI feed degraded)
max pain strike: $15.00 · spot: $14.13 · call volume: 26 · put volume: 59
Expected Move to 2026-06-18:
±$4.70
(33.26%) —
implied range
$9.43 –
$18.83
· ATM straddle on $15.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| KOD | Kodiak Sciences Inc. | $2.25B | $36.00 | — |
| MEOBF | MESOBLAST LTD | $2.20B | $1.70 | — |
| BCRX | BIOCRYST PHARMACEUTICALS INC | $2.15B | $8.47 | — |
| TARS | Tarsus Pharmaceuticals, Inc. | $2.63B | $61.16 | — |
| MESO | MESOBLAST LTD | $1.93B | $14.90 | — |
News headlines (Yahoo Finance, 1h cache)
Harvest Investment Services Dumps 356,000 Adaptive Biotechnologies (ADPT) Shares Worth $5.7 Million
2026-05-26 20:23 · Yahoo
Adaptive Biotechnologies to Participate in Upcoming Investor Conferences
2026-05-21 20:17 · Yahoo
Assessing Adaptive Biotechnologies (ADPT) Valuation After Strong MRD Growth And Raised Full Year Guidance
2026-05-11 06:07 · Yahoo
Adaptive Biotechnologies (ADPT) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
2026-05-05 22:30 · Yahoo
Adaptive Biotechnologies Q1 Earnings Call Highlights
2026-05-05 22:23 · Yahoo
Adaptive Biotechnologies (ADPT) Reports Q1 Loss, Beats Revenue Estimates
2026-05-05 22:05 · Yahoo
Adaptive Biotechnologies Reports First Quarter 2026 Financial Results
2026-05-05 20:05 · Yahoo
Adaptive Biotechnologies' Chief Operating Officer Sold Over 19,000 Company Shares. Here's What That Means for Investors.
2026-05-04 21:49 · Yahoo
How The Investment Story For Adaptive Biotechnologies (ADPT) Is Shifting With New Street Assumptions
2026-05-03 05:10 · Yahoo
Adaptive Biotechnologies' COO Is Running a Systematic Sell Program — Here's What It Means
2026-04-20 13:12 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.